# Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

> **NCT06982274** · PHASE2 · RECRUITING · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 115 (estimated)

## Conditions studied

- Acute Promyelocytic Leukemia (APL)

## Interventions

- **DRUG:** Realgar-Indigo Naturalis Formulation

## Key facts

- **NCT ID:** NCT06982274
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-20
- **Primary completion:** 2028-11
- **Final completion:** 2029-11
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982274, "Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06982274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*